Statement in solidarity with PLHIV demanding access to HIV/AIDS medications

The Delhi Network of Positive People (DNP+), a network of people living with HIV (PLHIV), has been protesting for over a month outside the office of National AIDS Control Organisation (NACO) in Delhi. They are protesting against the ongoing shortage of Anti-Retroviral Therapy (ART) medicines. The shortage has been raging for more than five months due to alleged discrepancies in the procurement of these medicines by NACO. As per the guidelines set out in the National AIDS Control Programme (NACP), NACO is responsible for supplying these medicines to 680 ART centres spread across the country.

Read the entire statement with the list of signatories. 


Health groups welcome price fixation of cardiac stents by NPPA

Health groups welcomed the notification by the National Pharmaceutical Pricing Authority (NPPA) of ceiling prices for coronary stents. The NPPA has notified a ceiling price for Drug Eluting Stents (DES) at Rs.29,600 and for Bare Metal Stents (BMS) at Rs.7,260 under the provisions of paragraph 19 of the Drugs Prices Control Order, 2013…read full statement here.

Read recent articles on the issue here and here.

Also read the notification by NPPA here..

Jan Swasthya Abhiyan Expresses Concern and Shock at the Lifting of the ban order on 344 FDCs

The Jan Swasthya Abhiyan (JSA) expresses its deepest concern
and shock at the verdict of the Delhi High Court, lifting the ban
imposed on 344 Fixed Dose Combinations (FDCs) of drugs by the
Government a few months back. This is a huge setback to efforts
aimed at bringing a semblance of order into the absolute
anarchy that exist in India’s pharmaceutical market…Read the JSA Press Release

Ban on FDCs: Public Health Must Prevail Over Corporate Profits

The Jan Swasthya Abhiyan compliments the Government for notifying a list of over 300 drug formulations, available as fixed‐dose combinations (FDCs) of two or more drugs, which are to be banned with immediate effect on the grounds of lack of “lack of therapeutic justification”. This is a long pending measure and needs to be followed up by further action to weed out a huge number of formulations, that should not have received marketing approval in the first place. Read JSA Press Release…